14-3-3η is a novel mediator associated with the pathogenesis of rheumatoid arthritis and joint damage

Arthritis Research and Therapy

Volumn 16, Issue 2, 2014, Pages

  Maksymowych, Walter P ^a   van der Heijde, Désirée ^b   Allaart, Cornelia F ^b   Landewé, Robert ^c   Boire, Gilles ^d   Tak, Paul P ^c,e   Gui, Yuan ^f   Ghahary, Aziz ^g   Kilani, Ruhangiz ^g   Marotta, Anthony ^f  

^a UNIVERSITY OF ALBERTA   (Canada)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d UNIVERSITY OF SHERBROOKE   (Canada)

^e GLAXOSMITHKLINE   (United Kingdom)

^f Augurex Life Sciences Corp   (Canada)

^g UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GELATINASE B; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; OSTEOCLAST DIFFERENTIATION FACTOR; PREDNISONE; RHEUMATOID FACTOR; STEROID; STRATIFIN; TUMOR NECROSIS FACTOR INHIBITOR; BIOLOGICAL MARKER; PROTEIN 14 3 3; YWHAH PROTEIN, HUMAN;

ADULT; ARTICLE; CLINICAL ARTICLE; DAS28; DISEASE COURSE; ENZYME ACTIVATION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MALE; MONOCYTE; PROTEIN BLOOD LEVEL; RADIOGRAPHY; RHEUMATOID ARTHRITIS; STEROID THERAPY; AGED; BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY; JOINT; MIDDLE AGED; PATHOLOGY;

14-3-3 PROTEINS; ADULT; AGED; ARTHRITIS, RHEUMATOID; BIOMARKERS; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; JOINTS; MALE; MIDDLE AGED;

EID: 84900404263     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4547     Document Type: Article

References (41)

1. Tak PP, Smeets TJ, Daha MR, Kluin PM, Meijers KA, Brand R, Meinders AE, Breedveld FC. Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity. Arthritis Rheum 1997, 40:217-225. 10.1002/art.1780400206, 9041933.
2. Verstappen SM, Bijlsma JW, Verkleij H, Buskens E, Blaauw AA, ter Borg EJ, Jacobs JW, . Utrecht Rheumatoid Arthritis Cohort Study Group Overview of work disability in rheumatoid arthritis patients as observed in cross-sectional and longitudinal surveys. Arthritis Rheum 2004, 51:488-497. 10.1002/art.20419, 15188338, Utrecht Rheumatoid Arthritis Cohort Study Group.
3. Vermeer M, Kuper HH, Hoekstra M, Haagsma CJ, Posthumus MD, Brus HL, van Riel PL, van de Laar MA. Implementation of a treat-to-target strategy in very early rheumatoid arthritis: results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort study. Arthritis Rheum 2011, 63:2865-2872. 10.1002/art.30494, 21647867.
4. de Rooy DP, van der Linden MP, Knevel R, Huizinga TW, van der Helm-van Mil AH. Predicting arthritis outcomes-What can be learned from the Leiden Early Arthritis Clinic?. Rheumatology (Oxford) 2011, 50:93-100. 10.1093/rheumatology/keq230, 20639266.
5. Kilani RT, Maksymowych WP, Aitken A, Boire G, St-Pierre Y, Li Y, Ghahary A. Detection of high levels of 2 specific isoforms of 14-3-3 proteins in synovial fluid from patients with joint inflammation. J Rheumatol 2007, 34:1650-1657.
6. Marotta A, Landewé R, van der Heijde D, Tak PP, Maksymowych. Serum 14-3-3η: a novel biomarker of rheumatoid arthritis [Abstract SAT0406]. Ann Rheum Dis 2011, 70:654.
7. Maksymowych WP, Landewé R, van der Heijde D, Tak PP, Marotta A. Serum 14-3-3: a rheumatoid arthritis biomarker [Abstract]. Arthritis Rheum 2011, 63:358.
8. Marotta A, Bykerk V, Siminovitch KA, Boers M, Landewé R, van der Heijde D, Tak PP, Genovese MC, Weinblatt ME, Maksymowych WP. Extracellular 14-3-3: an early rheumatoid arthritis pathogenic factor [Abstract]. Arthritis Rheum 2011, 63:378.
9. Clayton A, Turkes A, Navabi H, Mason MD, Tabi Z. Induction of heat shock proteins in B-cell exosomes. J Cell Sci 2005, 118:3631-3638. 10.1242/jcs.02494, 16046478.
10. Lancaster GI, Febbraio MA. Exosome-dependent trafficking of HSP70: a novel secretory pathway for cellular stress proteins. J Biol Chem 2005, 280:23349-23355. 10.1074/jbc.M502017200, 15826944.
11. Chavez-Muñoz C, Kilani RT, Ghahary A. Profile of exosomes related proteins released by differentiated and undifferentiated human keratinocytes. J Cell Physiol 2009, 221:221-231. 10.1002/jcp.21847, 19530224.
12. Quintana FJ, Cohen IR. The HSP60 immune system network. Trends Immunol 2011, 32:89-95. 10.1016/j.it.2010.11.001, 21145789.
13. Siebuhr AS, Bay-Jensen AC, Leeming DJ, Platt A, Byrjalsen I, Christiansen C, van der Heijde D, Karsdal MA. Serological identification of fast progressors of structural damage with rheumatoid arthritis. Arthritis Res Ther 2013, 15:R86. 10.1186/ar4266, 23945134.
14. Kook SH, Jang YS, Lee JC. Involvement of JNK-AP-1 and ERK-NF-κB signaling in tension-stimulated expression of type I collagen and MMP-1 in human periodontal ligament fibroblasts. J Appl Physiol 2011, 111:1575-1583. 10.1152/japplphysiol.00348.2011, 21757573.
15. Kapila S, Xie Y, Wang W. Induction of MMP-1 (collagenase-1) by relaxin in fibrocartilaginous cells requires both the AP-1 and PEA-3 promoter sites. Orthod Craniofac Res 2009, 12:178-186. 10.1111/j.1601-6343.2009.01451.x, 2753518, 19627519.
16. Noh EM, Kim JS, Hur H, Park BH, Song EK, Han MK, Kwon KB, Yoo WH, Shim IK, Lee SJ, Youn HJ, Lee YR. Cordycepin inhibits IL-1β-induced MMP-1 and MMP-3 expression in rheumatoid arthritis synovial fibroblasts. Rheumatology (Oxford) 2009, 48:45-48.
17. Kumar D, Ray A, Ray BK. Transcriptional synergy mediated by SAF-1 and AP-1: critical role of N-terminal polyalanine and two zinc finger domains of SAF-1. J Biol Chem 2009, 284:1853-1862.
18. Kyttaris VC. Kinase inhibitors: a new class of antirheumatic drugs. Drug Des Devel Ther 2012, 6:245-250. 3457674, 23055694.
19. de Launay LD, van de Sande MG, de Hair MJ, Grabiec AM, van de Sande GP, Lehmann KA, Wijbrandts CA, van Baarsen LG, Gerlag DM, Tak PP, Reedquist KA. Selective involvement of ERK and JNK mitogen-activated protein kinases in early rheumatoid arthritis (1987 ACR criteria compared to 2010 ACR/EULAR criteria): a prospective study aimed at identification of diagnostic and prognostic biomarkers as well as therapeutic targets. Ann Rheum Dis 2012, 71:415-423. 10.1136/ard.2010.143529, 3277721, 21953337.
20. Grattendick KJ, Nakashima JM, Feng L, Giri SN, Margolin SB. Effects of three anti-TNF-α drugs: etanercept, infliximab and pirfenidone on release of TNF-α in medium and TNF-α associated with the cell in vitro. Int Immunopharmacol 2008, 8:679-687. 10.1016/j.intimp.2008.01.013, 18387510.
21. Boire G, Cossette P, de Brum-Fernandes AJ, Liang P, Niyonsenga T, Zhou ZJ, Carrier N, Daniel C, Ménard HA. Anti-Sa antibodies and antibodies against cyclic citrullinated peptide are not equivalent as predictors of severe outcomes in RA patients with recent-onset polyarthritis. Arthritis Res Ther 2005, 7:R592-R603. 10.1186/ar1719, 1174957, 15899046.
22. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, Zwinderman AH, Ronday HK, Han KH, Westedt ML, Gerards AH, van Groenendael JH, Lems WF, van Krugten MV, Breedveld FC, Dijkmans BA. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005, 52:3381-3390. 10.1002/art.21405, 16258899.
23. Marotta A, van Kuijk AW, Maksymowych WP, Tak PP. Baseline serum 14-3-3η levels predict ACR50 response to adalimumab therapy in psoriatic arthritis [Abstract 0944]. Ann Rheum Dis 2010, 71:692.
24. de Vries-Bouwstra JK, Goekoop-Ruiterman YP, Verpoort KN, Schreuder GM, Ewals JA, Terwiel JP, Ronday HK, Kerstens PJ, Toes RE, de Vries RR, Breedveld FC, Dijkmans BA, Huizinga TW, Allaart CF. Progression of joint damage in early rheumatoid arthritis: association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies. Arthritis Rheum 2008, 58:1293-1298. 10.1002/art.23439, 18438829.
25. Sun S, Wong EW, Li MW, Lee WM, Cheng CY. 14-3-3 and its binding partners are regulators of protein-protein interactions during spermatogenesis. J Endocrinol 2009, 202:327-336. 10.1677/JOE-09-0041, 2804912, 19366886.
26. Dougherty MK, Morrison DK. Unlocking the code of 14-3-3. J Cell Sci 2004, 117:1875-1884. 10.1242/jcs.01171, 15090593.
27. Yaffe MB. How do 14-3-3 proteins work? Gatekeeper phosphorylation and the molecular anvil hypothesis. FEBS Lett 2002, 513:53-57. 10.1016/S0014-5793(01)03288-4, 11911880.
28. Marotta A, Gui Y, Kilani R, Ghahary A, Maksymowych WP. Extracellular 14-3-3η: a novel therapeutic target for inflammatory arthritis [Abstract OP0219]. Ann Rheum Dis 2011, 70:142.
29. Newell CL, Deisseroth AB, Lopez-Berestein G. Interaction of nuclear proteins with an AP-1/CRE-like promoter sequence in the human TNF-α gene. J Leukoc Biol 1994, 56:27-35.
30. Wu Q, Liu CZ, Tao LY, Yu L, Liu W, Chen SS, He XD. The clinicopathological and prognostic impact of 14-3-3 protein isoforms expression in human cholangiocarcinoma by immunohistochemistry. Asian Pac J Cancer Prev 2012, 13:1253-1259. 10.7314/APJCP.2012.13.4.1253, 22799314.
31. Nakamura Y, Oshima K, Naoi Y, Nakayama T, Kim SJ, Shimazu K, Shimomura A, Maruyama N, Tamaki Y, Noguchi S. 14-3-3σ expression is associated with poor pathological complete response to neoadjuvant chemotherapy in human breast cancers. Breast Cancer Res Treat 2012, 134:229-236. 10.1007/s10549-012-1976-x, 22315133.
32. Zhou WH, Tang F, Xu J, Wu X, Feng ZY, Li HG, Lin DJ, Shao CK, Liu Q. Aberrant upregulation of 14-3-3o{horn} expression serves as an inferior prognostic biomarker for gastric cancer. BMC Cancer 2011, 11:397. 10.1186/1471-2407-11-397, 3184120, 21933426.
33. Ko BS, Chang TC, Hsu C, Chen YC, Shen TL, Chen SC, Wang J, Wu KK, Jan YJ, Liou JY. Overexpression of 14-3-3ε predicts tumour metastasis and poor survival in hepatocellular carcinoma. Histopathology 2011, 58:705-711. 10.1111/j.1365-2559.2011.03789.x, 21401702.
34. Boesenberg-Grosse C, Schulz-Schaeffer WJ, Bodemer M, Ciesielczyk B, Meissner B, Krasnianski A, Bartl M, Heinemann U, Varges D, Eigenbrod S, Kretzschmar HA, Green A, Zerr I. Brain-derived proteins in the CSF, do they correlate with brain pathology in CJD?. BMC Neurol 2006, 6:35. 10.1186/1471-2377-6-35, 1592107, 16989662.
35. Jayaratnam S, Khoo AK, Basic D. Rapidly progressive Alzheimer's disease and elevated 14-3-3 proteins in cerebrospinal fluid. Age Ageing 2008, 37:467-469. 10.1093/ageing/afn094, 18460497.
36. Colucci M, Roccatagliata L, Capello E, Narciso E, Latronico N, Tabaton M, Mancardi GL. The 14-3-3 protein in multiple sclerosis: a marker of disease severity. Mult Scler 2004, 10:477-481. 10.1191/1352458504ms1089oa, 15471360.
37. Umahara T, Uchihara T, Tsuchiya K, Nakamura A, Iwamoto T. Intranuclear localization and isoform-dependent translocation of 14-3-3 proteins in human brain with infarction. J Neurol Sci 2007, 260:159-166. 10.1016/j.jns.2007.04.053, 17561120.
38. Miller RF, Green AJ, Giovannoni G, Thompson EJ. Detection of 14-3-3 brain protein in cerebrospinal fluid of HIV infected patients. Sex Transm Infect 2000, 76:408.
39. Maksymowych WP, Landewé R, Tak PP, Ritchlin CJ, Ostergaard M, Mease PJ, El-Gabalawy H, Garnero P, Gladman DD, Fitzgerald O, Aletaha D, Bykerk VP, Bathon JM, Syversen SW, Boers M, Geusens P, Inman RD, Kraus VB, Kvien TK, Taylor WJ, Wells GA, van der Heijde D. Reappraisal of OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage endpoints in rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis: the OMERACT 9 v2 criteria. J Rheumatol 2009, 36:1785-1791. 10.3899/jrheum.090346, 19671813.
40. Marotta A, Kilani R, Ghahary A, Maksymowych WP. Extracellular 14-3-3η represents a novel rheumatology biomarker and drug target for personalized medicine [Abstract AB0111]. Ann Rheum Dis 2012, 71:644.
41. Britsemmer K, Maksymowych WP, van Schaardenburg D, Marotta A. 14-3-3η is an early RA biomarker that is modifiable with standard DMARDs and corresponds with improvement in clinical variables. Ann Rheum Dis 2013, 72:388.